Indivior PLC (LON:INDV)‘s stock had its “buy” rating reiterated by stock analysts at Numis Securities Ltd in a report released on Tuesday, July 11th, Marketbeat.com reports. They currently have a GBX 490 ($6.38) target price on the specialty pharmaceutical company’s stock. Numis Securities Ltd’s price objective would suggest a potential upside of 22.41% from the stock’s previous close.
A number of other analysts also recently issued reports on INDV. Royal Bank Of Canada downgraded shares of Indivior PLC to a “sector performer” rating and increased their target price for the stock from GBX 370 ($4.82) to GBX 390 ($5.08) in a research report on Monday, March 13th. Stifel Nicolaus reissued a “buy” rating and set a GBX 500 ($6.51) target price on shares of Indivior PLC in a research report on Tuesday, April 4th. Finally, Jefferies Group LLC reissued a “buy” rating and set a GBX 490 ($6.38) target price on shares of Indivior PLC in a research report on Thursday, May 4th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of GBX 447.50 ($5.83).
Indivior PLC (LON INDV) traded down 0.40% on Tuesday, hitting GBX 400.30. 2,291,953 shares of the stock traded hands. The stock’s market cap is GBX 2.89 billion. Indivior PLC has a 12-month low of GBX 266.60 and a 12-month high of GBX 404.20. The firm’s 50-day moving average price is GBX 333.61 and its 200-day moving average price is GBX 330.09.
ILLEGAL ACTIVITY NOTICE: “Indivior PLC’s (INDV) “Buy” Rating Reaffirmed at Numis Securities Ltd” was published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/numis-securities-ltd-reaffirms-buy-rating-for-indivior-plc-indv-updated-updated-updated/1194750.html.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with our FREE daily email newsletter.